|
|
|
|
|
|
|
|
|
|
|
|
|
19.05.26 - 18:18
|
Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t a Slam Dunk (24/7 Wall St.)
|
|
|
BridgeBio Pharma (NASDAQ:BBIO) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company's transthyretin amyloid cardiomyopathy (ATTR-CM) franchise. The call contrasts with Citi's simultaneous Buy initiation Buy ratings on peer biotechs Alnylam, Ascendis Pharma, BioMarin, Cytokinetics, and of Ionis Pharmaceuticals (NASDAQ:IONS), making the BBIO Neutral a cautious outlier. For ... Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn't a Slam Dunk...
|
|
|
|
|
|
|
|
|
13.05.26 - 13:33
|
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer (Business Wire)
|
|
|
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Muzammil Mustufa as Chief Business Officer (CBO). Mr. Mustufa will oversee corporate strategy, business development, commercial planning, and investor relations efforts.
Mr. Mustufa brings 20 years of diversified pharmaceutical and biotechnology experience to Zura, with extensive experience in immunology, rare disease, and other therapeutic areas. Most recently, he served as Vice President of Corporate Strategy at Amicus Therapeutics, where he played an integral part in the global launch and commercialization strategies of two innovative medicines in orphan diseases. He subsequently led integration planning for Amicus in connection with BioMarin Pharmaceutical Inc.'s $4.8 billion acquisition of t...
|
|
|
|
|
11.05.26 - 14:00
|
Here Are Monday′s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More (24/7 Wall St.)
|
|
|
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as reports indicate that President Trump declined Iran's counteroffer for peace. This comes after a remarkable Friday, when stocks roared to record highs, driven primarily by a stronger-than-expected April jobs report that eased economic concerns and by a ... Here Are Monday's Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy's, and More...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
